Pulmonary Function Tests (PFTs) are vital tools in diagnosing and managing respiratory diseases. However, their interpretation can be complex, requiring a comprehensive understanding of respiratory physiology and pathology. This article aims to elucidate the key aspects of PFTs, aiding healthcare professionals in their clinical practice.
Spirometry measures the volume and speed of air that can be inhaled and exhaled, providing key metrics such as Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1). A reduced FEV1/FVC ratio suggests obstructive lung disease, while a reduced FEV1 and FVC with a normal ratio indicates restrictive lung disease.
These tests measure the lung's ability to transfer gas from air to red blood cells. The most common is the Diffusion Capacity for Carbon Monoxide (DLCO). A decreased DLCO can suggest interstitial lung disease, pulmonary vascular disease, or emphysema.
Lung volume measurements provide information about the size of the lungs and the presence of hyperinflation or gas trapping. Total Lung Capacity (TLC) is a key measurement, and a reduction may indicate restrictive disease. Residual Volume (RV) can be elevated in obstructive diseases.
Exercise testing assesses the integrated responses of the pulmonary and cardiovascular systems. It can identify exercise-induced bronchospasm, desaturation, and cardiovascular limitations to exercise.
Decoding PFTs requires an understanding of multiple test components and their interrelationships. It is essential to interpret the results in the context of the patient's clinical presentation, as the same PFT abnormalities can occur in different diseases. With a comprehensive understanding of these tests, healthcare professionals can accurately diagnose and optimize the management of respiratory conditions.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation